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APC = antigen presenting cell; DC = dendritic cell; HLA = human leukocyte antigen; RA = rheumatoid arthritis; RF = rheumatoid factor;
Th cell = T helper cell; TNF = tumor necrosis factor.
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Introduction
It is believed that the pathology and etiology of rheumatoid
arthritis involves abnormal presentation of self antigen(s) by
APCs and activation of autoreactive T cells [1]. T lympho-
cytes have therefore been proposed to play a central role in
the disease process [2•], the most powerful evidence for
which is the association of the disease with certain human
leukocyte antigen (HLA)-DR chains that are shared
between various alleles of HLA-DR4 and HLA-DR1 [3,4].
The rheumatoid synovial membrane is rich in major histo-
compatibility complex class II+ APCs, and CD4+ T cells
make clusters with such HLA-DR-positive cells [5]. The
T cells present in the RA synovium express the activation
markers HLA-DR, VLA-4 and CD69. However, it is not clear
whether T cell activation occurs before entry to the tissue,
during transendothelial migration, or in the synovium. APCs
require signals from activated T cells for their differentiation
and maturation [6]; this subsequently enables APCs to acti-
vate newly arrived T cells in a specific or unspecific manner
in the local inflammation (Fig. 1). Activated T cells promote
the disease progression by inducing the secretion of pro-
inflammatory cytokines (in particular, tumor necrosis factor
[TNF]-a) from macrophages and synovial cells in a contact-
dependent manner [7,8].
Several costimulatory molecules are involved during
APC–T cell interactions, including CD28/CD80-86 and
CD40-CD40L. Some of these molecules are thought to
be critical in initiation of the immune response
(CD28/CD80/86), while CD40-CD40L are required for
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the amplification of the inflammatory response [9••]. This
paper reviews the costimulatory molecules and types of
APCs involved in local APC–T cell interactions and their
possible roles in the disease pathology.
Costimulatory molecules and T cell activation
in the synovium
Initial T cell activation is dependent on T cell receptor trigger-
ing and costimulatory signaling through CD28-CD80/CD86
[10,11]. APCs such as dendritic cells (DCs),
macrophages, B cells and follicular DCs can provide both
of these signals. APCs that cannot provide costimulatory
signals are unable to activate naïve T cells unless a
second signal is provided by accessory APCs. The cos-
timulatory molecules CD80/CD86 are expressed at
varying levels by APCs in the synovium. Expression of
CD80 is generally low, while the expression of CD86 is
relatively high and is expressed on several APCs includ-
ing DCs, B cells and macrophages [12,13]. It has been
suggested that CD80/CD86 interactions influence the
development of T helper (Th)1 and Th2 cells, where Th2
polarization is dependent on signals through the CD80
molecule [14•,15]. T cells in the synovium are of Th1 type,
and even though the secretion of IFNg is low, the Th1
cytokine IL-17 can be found in high levels [16,17].
Expression of CD86 and lack of CD80 then correlates
with the dominant population of Th1 cells in the synovium
[16,18]. APCs in the synovium might therefore be
capable of the initial activation of T cells through the Th1
pathway by the expression of CD86 and secretion of
IL-12. It has been shown in various models that blocking
the CD28 signaling pathway can prevent or treat autoim-
mune diseases [19,20]. Studies in MLR/lpr mice lacking
CD28 suggest that CD28 is most probably a regulator in
the induction of autoimmune diseases. Arthritis is abol-
ished and autoantibody production is suppressed in
these mice, but the accumulation of abnormal T cells is
almost unchanged [21].
The memory population of Th1 cells in the synovium has
an increased number of CD28-negative cells [22].
Memory T cells, however, have a lower requirement for
CD28 signaling compared with naïve T cells and can
respond to T cell receptor signaling alone [23]. A much
greater range of APCs can therefore stimulate memory
T cells than that which stimulates naïve T cells. In addition,
effector T cells are even less dependent on costimulatory
signals and can respond to many types of APC including
resting B cells and macrophages [24]. APCs in the syn-
ovium generally express low levels of CD80/86, but still
might function as APCs for memory/effector T cells and
maintain the inflammatory response by continuously acti-
vating synovial memory T cells.
In addition to CD28/CD86-80 costimulation, CD40-CD40L
has been shown to contribute to T cell activation, both by
independently costimulating T cells and, at least in part, by
upregulating CD80/CD86 molecules on APCs [14•,25].
The CD40 pathway is particularly thought to be important
for amplification of the T cell response, as blocking the
CD40 signaling pathway has been shown to inhibit Th1 dif-
ferentiation and maintenance of the immune response [26].
DCs, B cells and macrophages express CD40 in the syn-
ovium, and these APCs may be of particular importance for
the disease pathogenesis.
DC–T cell interaction
Fully mature DCs are found in the perivascular area in
close association with T cells and with B-cell follicles, and
express markers associated with mature DCs, including
major histocompatibility complex class II molecules,
nuclear RelB, adhesion molecules and STAT 4 [5,27].
DCs migrate from peripheral blood, probably under the
influence of a chemotactic attractant to the synovial
tissue [28]. DCs in the synovium receive differentiation
signals from monocyte derived cytokines and through
CD40L interaction with T cells. DCs are located adjacent
to endothelial cells surrounding blood vessels in the syn-
ovium, implying that DCs derived from circulating precur-
sors may have differentiated during a short time after
transendothelial migration. If this is so, DCs could func-
tion as potent antigen presenting cells, either for external
or local antigen(s) released by the ongoing synovial
inflammation. Several cytokines are produced in RA syn-
ovium, including TNFa, IL-1 and granulocyte
macrophage-colony stimulating factor, that can upregu-
late the ability of DCs to present antigen. The major DC
differentiation signal is achieved through ligation of
CD40, which triggers high levels of IL-12 secretion and
Figure 1
Antigen presenting cell–T cell interaction in the synovium. Dendritic
cells (DCs) in the synovium present an external or local antigen to T
cells. T cell receptor interaction and signaling via CD28-CD80/86 are
essential for initial T cell activation leading to upregulation of CD40L on
the T cells. Activated T cells are then capable of inducing further
differentiation of DCs, as well as T cell help to rheumatoid factor B cells
that have taken up antigen–Ig complexes. CD40-CD40L interaction
between DCs, B cells and T cells may play a critical role in repeated
activation of memory T cells in the synovium and, thus, maintenance of
the inflammatory reactions.c
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upregulation of CD80, CD86 and ICAM-1 [29,30]. T cells
in the synovium express CD40L and, upon interaction
with DCs, play an important role in upregulation of the
antigen presenting capacity of synovial tissue DCs [31].
A high number of mature DCs are then able to polarize
the T cell response into the Th1 pathway, giving the Th1
cells an irreversible phenotype [32].
Antigen presentation by rheumatoid factor B
cells and T cell interaction
B cells are another major source of APCs in the syn-
ovium. Rheumatoid factor (RF) B cells, in particular, are
believed to play an important role in antigen presentation
[33••]. RF B cells can take up antigen–Ig immune com-
plexes via their membrane Ig receptors, which have RF
specificity and thus react with the IgG Fc part of antibody
molecules. The B cells then process and present pep-
tides from the antigen, and thus induce both T cell activa-
tion and T cell help for multiple antigens, as well as T cell
help for RF secretion (Fig. 1). High affinity RFs accumu-
late in the synovium and contribute to the disease patho-
genesis by forming immune complexes and activation of
complement [34]. Low affinity RFs are abundant in lymph
nodes in healthy individuals, and high affinity RFs are
deleted in mice [35,36]. The reason for the persistence of
high affinity RFs in RA patients but not in healthy individu-
als is not fully understood. However, in normals there are
mechanisms that prevent replacement mutations which
can lead to affinity maturation. Thus, the R:S ratio in the
CDR regions are found to be extrememely low [37]. In the
synovium, RF B cells produce RFs with multiple replace-
ment mutations in their variable regions, and many
undergo class switching and affinity maturation. This indi-
cates an antigen and T cell driven process [38,39].
CD40L expressing, activated T cells [31] can, upon
binding with CD40 on B cells, induce proliferation, anti-
body production and isotype switch. CD40L is upregu-
lated on T cells after activation by DCs, and this suggests
that recently primed T cells are recruited for B cell help
and affinity maturation, in a similar mechanism as occurs
in the lymph node. The crucial role of CD40 signaling for
RF production has been demonstrated in RF transgenic
mice that lack mature T and B cells but have rearranged
RF B cells. Anti-CD40 antibody could stimulate RF pro-
duction as efficiently as T cells in these mice. Deletion of
RF B cells by human IgG could also be blocked using
anti-CD40 antibody [40•]. The importance of CD40 sig-
naling in autoantibody production has also been shown
by studies in lupus-prone mice where IgG autoantibodies
are reduced after blocking CD40 signaling [41]. Synovio-
cytes can, in addition, support terminal B cell survival and
differentiation, even though the involvement of CD40 in
these interactions is not clear [42]. T cell signaling
through CD40/CD40L appears to be a major factor in the
inhibition of apoptosis of high affinity RF B cells, as well
as in the production of RF.
Monocytes as APCs
Most synovial macrophages are located in the lining layer,
where they are thought to be major contributors to cytokine
production and joint destruction. The synovial
macrophages are in an activated stage and have an
increased expression of HLA-DR, which enhances their
antigen presenting capacity [43]. Synovial macrophages,
like DCs and B cells, express the costimulatory molecule
CD86 [44]. Synovial macrophages have also been shown
to express STAT 4, which further demonstrates their acti-
vated stage and also indicates a role of these cells in IL-12
secretion and activation/polarization of Th1 cells [45]. IFNg
is known to be a potent activator of macrophages, but the
level of IFNg in the synovium is very low [46]. It has there-
fore been argued that granulocyte macrophage-colony
stimulating factor, which performs many similar roles to
IFNg, may play a more important role in the activation of
macrophages. Synovial T cells have also been shown to
activate macrophages upon cell–cell interaction where
CD40L interaction is important to induce cytotoxicity,
HLA-DR expression and cytokine production. Synovial
monocytes are shown to be more efficient APCs than their
counterparts isolated from peripheral blood [47]. Even so,
macrophages may not be important in antigen presenta-
tion, as they are mainly located in the synovial lining that is
distant from the T cell rich area. However, some
macrophages are located in the perivascular area, and
these might have specialized APC functions compared
with the macrophages in the lining layer, as the former
express nuclear RelB and CD68 [48].
Conclusion
There is considerable evidence indicating an ongoing aber-
rant immune response in the synovial tissues of RA patients.
This is critically dependent on the activation of T cells, and
much of the resulting tissue destruction is a consequence
of the resulting pro-inflammatory cytokine production. The
clinical importance of these cytokines has been demon-
strated by anti-TNFa therapies in rheumatoid arthritis
patients, which have been shown to be powerful treatments
for the majority of RA patients, although a substantial minor-
ity does not respond [49]. An alternative approach to treat-
ment could be to reduce T cell activation by the blocking of
upstream events, particularly the costimulatory signaling
pathways involved during APC–T cell interaction.
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